Peptide News Digest

#Pth-Peptide

2 stories

Clinical Trials · View digest

Ascendis Pharma 5-Year TransCon PTH PaTH Forward Data: 82% Off Active Vitamin D and Calcium at Week 266, 95% Trial Completion

Ascendis Pharma (Nasdaq: ASND) released June 11 the 5-year (Week 266) results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) in adults with chronic hypoparathyroidism, ahead of formal presentation at ENDO 2026 in Chicago. At Week 266, 82% of patients met the composite endpoint of normal serum calcium without active vitamin D and with less than 600 mg/day of calcium; nearly all participants achieved independence from conventional therapy, and 95% completed the full five years. TransCon PTH replicated endogenous PTH across kidney, intestine, CNS, and bone, with normalized urine and serum calcium, sustained bone mineral density, and quality-of-life gains. The data directly stress-tests MBX Biosciences's once-weekly canvuparatide Phase 2 readout from June 12, which posted 63% responder at 12 weeks and 57% at one year.

Clinical Trials · View digest

MBX Biosciences Canvuparatide Hits 63% Responder Rate in Phase 2 Avail, Sustains Through One-Year Open-Label Extension, Phase 3 Set for Q3 2026

MBX Biosciences (Nasdaq: MBX) on June 12 reported full 12-week Phase 2 Avail data and one-year open-label extension results for once-weekly canvuparatide, a precision PTH peptide for chronic hypoparathyroidism. The trial hit its primary endpoint with a 63% responder rate versus 31% on placebo at 12 weeks; the OLE delivered a 79% responder rate at six months and 57% at one year. Patients showed normalized serum calcium, reduced urine calcium excretion, restored bone metabolism, and improved eGFR; 90% of OLE patients remained on study at one year with no new safety signals. A registrational Phase 3 in chronic hypoparathyroidism starts Q3 2026.